Is ARKG a Buy? What to Consider in 2026

The ARK Genomic Revolution ETF (ARKG) is an actively-managed fund from Cathie Wood's ARK Invest that targets companies it believes will benefit from advances in genomics, gene editing, molecular diagnostics, and biotechnology. The portfolio is highly concentrated, typically holding around 30 to 35 names, with the top 10 positions making up roughly 60% of assets as of early 2026. It tilts heavily toward early-stage, pre-profit and clinical-stage biotech names, including CRISPR gene-editing companies, molecular-diagnostics firms, and AI-driven drug discovery platforms. ARKG carries a 0.75% expense ratio and has seen its assets fall sharply from a peak near $9 billion in early 2021 to roughly $1.2 billion in early 2026, reflecting both outflows and a deep drawdown in speculative biotech.

Largest holdings (approximate as of early 2026; verify on ARK Invest's fund page):

ARKG is Cathie Wood's actively-managed ARK Invest ETF focused on the genomics and biotech-innovation theme, holding names like CRISPR Therapeutics, Tempus AI, Twist Bioscience, and other molecular-diagnostics and gene-editing companies. It is highly concentrated, with around 30 to 35 holdings and the top 10 accounting for roughly 60% of assets. The fund is very volatile and has suffered a large drawdown since its 2021 peak, with assets falling from about $9 billion to roughly $1.2 billion. It is a high-risk thematic fund built around speculative, often unprofitable biotech companies.

In its favour: it gives you Actively managed (no index); focused on genomics and biotech innovation exposure in one ticker at a 0.75% expense ratio, which is simple to hold and cheap to own.

• Cost vs alternatives: 0.75% is the fee; compare it to funds tracking a similar index.
• Concentration: check how much of ARKG sits in its largest holdings (TWST, TEM, TXG).
• Overlap: if you already own a broad-market fund, you may already hold much of this.
• Tracking scope: ARKG only gives you Actively managed (no index); focused on genomics and biotech innovation; it will not capture what sits outside that index.

The useful question is rarely “will ARKG go up?” It is “does this exposure fit my plan, at a cost I am happy with, without doubling up on what I already own?” Walnut connects your real brokerage so you can see exactly how ARKG would overlap with your current holdings, analyze it by chatting through Claude or ChatGPT, and place any trade yourself. You stay in control.

The bottom line: ARKG is a low-cost core building block for Actively managed (no index); focused on genomics and biotech innovation exposure, not a tactical bet on a single name. If you want Actively managed (no index); focused on genomics and biotech innovation exposure and the 0.75% fee is competitive for you, it does its job well. If you already own that exposure through another fund, adding it mostly doubles a fee without adding diversification. Decide from your goal and your existing holdings, not from where the market sat last week. Walnut is not an investment adviser.